Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride by unknown
RESEARCH ARTICLE Open Access
Rates of prostate surgery and acute urinary
retention for benign prostatic hyperplasia
in men treated with dutasteride or
finasteride
Josephina G. Kuiper1*, Irene D. Bezemer1, Maurice T. Driessen2, Averyan Vasylyev3, Claus G. Roehrborn4,
Fernie J. A. Penning-van Beest1 and Ron M. C. Herings1
Abstract
Background: Previous studies have suggested a greater benefit for various outcomes in men diagnosed with
benign prostatic hyperplasia (BPH) who are treated with dutasteride than for men treated with finasteride. This
study investigates whether the rates of BPH-related prostate surgery and acute urinary retention (AUR) differ
between dutasteride and finasteride users in the Netherlands.
Methods: From the PHARMO Database Network, men aged ≥50 years with a dispensing of dutasteride or finasteride
with or without concomitant alpha-blocker treatment between March 1, 2003 and December 31, 2011 were selected.
The incidence of BPH-related prostate surgery and AUR was determined during dutasteride or finasteride treatment
and stratified by type of initial BPH-treatment (5-ARI monotherapy or combination with alpha-blocker) and prescriber
(general practitioner (GP) or urologist). Comparison of the incidence of BPH-related prostate surgery and AUR between
the treatment groups was done by Cox proportional hazard regression.
Results: 11,822 dutasteride users and 5,781 finasteride users were identified. Most users started treatment in
combination with an alpha-blocker. Overall, dutasteride users had a lower risk of BPH-related prostate surgery was
lower among dutasteride users than finasteride users (HR: 0.75; 95 % CI: 0.56–0.99). This lower risk among dutasteride
users was also seen when stratifying by monotherapy or combination therapy (HR: 0.73; 95 % CI: 0.54–0.98 for
monotherapy and HR: 0.85; 95 % CI: 0.74–0.97 for combination therapy). However, the association was only present
among men treated by urologists. For AUR the rates were low and no statistical significant difference was observed
between dutasteride and finasteride users.
Conclusions: The risk of undergoing BPH-related prostate surgery was lower among men using dutasteride compared
to men using finasteride. The association was observed for monotherapy as well as combination therapy, however,
only among men who received their prescription from a urologist.
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Background
Benign prostatic hyperplasia (BPH) affects 32–52 % of
men aged 51–60 years and 77–99 % of men ≥81 years of
age [1, 2]. Lower urinary tract symptoms (LUTS), such as
poor stream and hesitancy, are common in patients with
BPH. Progression of BPH may result in acute urinary
retention (AUR) and need for surgical procedures that
(partially) remove the prostate [3]. In order to relief BPH
related symptoms, alpha-adrenoreceptor antagonists
(“alpha-blockers”) can be used. Previous studies suggests
that the combination of alpha-blockers and 5-alpha reduc-
tase inhibitors (5-ARIs) can be beneficial in the treatment
of BPH associated with LUTS [4]. The greatest efficacy for
this combination treatment was shown in patients with a
large prostate size, a prostate-specific antigen (PSA) value
of > 1.5 ng/ml, and with moderate to severe symptoms
based on the International Prostate Symptom Score
(IPSS). They experienced significant symptom relief and a
decreased risk of AUR and surgery compared to patients
treated with monotherapy [5]. Dihydrotestosterone (DHT),
a metabolite of testosterone is the main mediator of pros-
tate growth. As a class, 5-ARIs aimed to reduce the size of
the prostate by blocking the activity of 5-alpha reductase
enzymes in converting testosterone to DHT [6, 7]. The
currently available 5-ARI agents in the United States and
European market (dutasteride and finasteride), have been
shown to reduce prostate volume by 20–30 % [8]. Long-
term use of 5-ARI agents results in symptomatic improve-
ments and reduction of the risk for AUR and prostate
surgery [6, 9, 10]. Dutasteride blocks the type 1 as well as
type 2 5-alpha reductase isoenzymes whereas finasteride
blocks only the type 2 isoenzyme. Suppression of serum
DHT has been shown to be more than 90 % by dutasteride
and 70 % by finasteride [7].
In retrospective studies, the efficacy of finasteride and
dutasteride has been compared for AUR and BPH-related
surgeries showing significantly lower rates of AUR and
BPH-related surgeries among dutasteride treated patients as
compared with finasteride treated patients [11]. In another
study, patients treated with dutasteride were less likely to
experience AUR and prostate surgery than patients treated
with finasteride [12]. A previous study conducted in Italy
showed that the incidence of BPH-related hospitalization
was lower among patients treated with dutasteride com-
pared to patients treated with finasteride [13].
The purpose of this study was to compare the rates of
BPH-related prostate surgery and AUR between dutaste-
ride and finasteride alone or in combination with an
alpha-blocker in the Dutch setting.
Methods
Data source
Data were obtained from the PHARMO Database Net-
work in the Netherlands. This population-based network
of healthcare databases combines data from different
healthcare settings. Data sources are linked on a patient
level through validated algorithms. The longitudinal na-
ture of the PHARMO Database Network system enables
to follow-up more than 4 million (25 %) residents of a
well-defined population in the Netherlands for an
average of ten years. For this study the Hospitalisation
Database, the Out-patient Pharmacy Database and the
General Practitioner (GP) Database were used. The Hos-
pitalisation Database comprises hospital admissions
from the Dutch Hospital Data Foundation [14], i.e.,
admissions for more than 24 h and admissions for less
than 24 h for which a bed is required. The records in-
clude information about discharge diagnoses, proce-
dures, and hospital admission and discharge dates.
Diagnoses are coded according to the International
Classification of Diseases [15] and procedures are coded
according to the Dutch Classification of Procedures [16].
The Out-patient Pharmacy Database comprises GP or
specialist prescribed healthcare products dispensed by
the out-patient pharmacy. The dispensing records in-
clude information about type of medicine, dispensing
date, strength, dosage regimen, quantity, route of admin-
istration, and prescriber specialty. Drug dispensings are
coded according to the World Health Organization
(WHO) Anatomical Therapeutic Chemical (ATC) Classi-
fication System. The GP Database comprises data from
electronic patient records registered by GPs. The records
include information on diagnoses and symptoms, labora-
tory test results, referrals to specialists and healthcare
product/drug prescriptions. Diagnoses and symptoms
are coded according to the International Classification of
Primary Care (ICPC) [17]. The prescription records in-
clude information on type of product, date, strength,
dosage regimen, quantity and route of administration.
Drug prescriptions are coded according to the WHO
ATC Classification System (WHO Anatomical Thera-
peutic Chemical Classification System) [18].
Study population
From the Out-patient Pharmacy Database, men aged
50 years or older who were treated with dutasteride or
finasteride between March 1, 2003 and December 31,
2011 were selected for inclusion in this study. The date
of the first dispensing was designated as cohort entry
date. Men were classified as either receiving 5-ARI mono-
therapy or 5-ARI in combination with an alpha-blocker at
cohort entry date. 5-ARI in combination with an alpha-
blocker was defined as continuous use of an alpha-blocker
at cohort entry date or starting an alpha-blocker within
7 days of cohort entry date. The alpha-blocker and 5-ARI
could be used as separate preparations or as combination
pill. From the selected population, we excluded 1) men
using 1 mg finasteride tablets (as these were indicated for
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the treatment of alopecia), and 2) men who had a
hospitalization for prostate surgery, urinary retention,
prostate cancer or bladder cancer before cohort entry
date. To be able to define comorbidities in recent history
and the risk of BPH-related prostate surgery, users were
required to have continuous enrollment in the PHARMO
Database Network of at least 12 months before and
12 months after the index date. All men were followed
from cohort entry until moving out of the PHARMO
catchment region, death, or end of the study period
(December 31, 2011), whichever occurred first.
Type of treatment
Dispensings of dutasteride, finasteride and alpha-blocker
at cohort entry date and during follow-up were con-
verted into treatment episodes of uninterrupted use. For
each drug dispensing the duration of use was calculated
by dividing the number of units dispensed by the num-
ber of units to be used per day, as defined in the dis-
pensing records. In case of an interruption between two
dispensings, use was considered uninterrupted if the
duration of this gap was less than half the period of the
given dispensing, or seven days, whichever is greater,
according to the method of Catalan [19]. Episodes of
uninterrupted use were constructed on the level of 5-
ARI (dutasteride and finasteride episodes) and on the
level of total BPH treatment (dutasteride monotherapy,
finasteride monotherapy, dutasteride combination ther-
apy or finasteride combination therapy). The first
episode of 5-ARI treatment ended at the dispensing date
of the alternative 5-ARI. The first episode of BPH treat-
ment ended when the dutasteride or finasteride episode
ended, when the alpha-blocker episode ended (for men
on combined therapy) or when an alpha-blocker was
dispensed (for men on monotherapy). Adherence with
5-ARI treatment during the first episode of BPH treat-
ment was reflected by the medication possession rate
(MPR), defined as the total number of days of 5-ARI
treatment, divided by the duration of episode.
Study endpoint
The primary endpoints in the current study were the
rate of BPH-related prostate surgery and AUR during
treatment with dutasteride compared to finasteride.
BPH-related prostate surgery was defined by surgical
procedures on the prostate during hospitalization with a
primary or secondary discharge diagnosis of BPH (either
coded as benign neoplasm or hyperplasia) and no diag-
nosis of prostate cancer. AUR was defined as a hospital
admission with a primary or secondary discharge diag-
nosis of urinary retention.
BPH-related prostate surgery and AUR were deter-
mined during the first episode of 5-ARI treatment. Sen-
sitivity analyses were performed by adding a washout
period of 6 months after discontinuation of 5-ARI treat-
ment to the observation period, and by limiting the ob-
servation period to the first episode of BPH treatment,
i.e. ending observation upon addition (for initial mono-
therapy) or discontinuation (for initial combination ther-
apy) of alpha-blocker therapy.
Data analysis
Incidence rates of BPH-related prostate surgery and
AUR were calculated by dividing the number of men
with the event under investigation by the person-time at
risk of the event under investigation in the population.
Rates were stratified by concomitant use of alpha-
blocker (mono- or combination therapy). As the setting
of care is an indicator of severity of disease and may as
well be related to surgery rates, results were also strati-
fied by initial prescriber (GP or urologist). Hazard ratios
(HR) and confidence intervals (CI) for comparison be-
tween the treatment groups were calculated using Cox
proportional hazards regression adjusting for con-
founders. Potential confounders were age, chronic
disease score (CDS), prescriber, adherence with 5-ARI
treatment (medication possession rate (MPR)), history
of bladder/kidney stones, urological care, haematuria,
PSA, duration of alpha-blocker use, hypertension,
hypercholesterolemia, diabetes type I, diabetes type II,
Parkinson’s disease, multiple sclerosis, number of hos-
pital admissions, number of drug dispensings (of any
drug), and number of GP visits. Potential covariates
that were associated with the outcome at an alpha of
5 % (univariate p < 0.05) and also were associated with
choice of 5-ARI (t-test p < 0.05 for continuous vari-
ables and chi-square p < 0.05 for categorical variables)
were included in the multivariate model if they chan-
ged the association between treatment and outcome
by at least 5 %. All HRs were adjusted for geographic
location to account for potential missing outcomes in
combination with local prescriber preference.
All data were analysed using SAS programs organized
within SAS Enterprise Guide version 4.3 (SAS Institute
Inc., Cary, NC, USA) and conducted under Windows
using SAS version 9.2.
Results
Patient characteristics
A total of 11,822 men treated with dutasteride (8,675 men
(73 %) on combination therapy) and 5,781 men treated
with finasteride (3,517 men (61 %) on combination ther-
apy) between March 1, 2003 and December 31, 2011 were
included in the analysis (Table 1). Most men on combin-
ation therapy were already using an alpha-blocker when
they started 5-ARI (68 % of the dutasteride users and 75 %
of the finasteride users). The mean age among the differ-
ent cohorts was approximately 70 years. The initial
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prescriber of the first dutasteride dispensing was a urolo-
gist (57 %), while the first finasteride dispensing was pri-
marily issued by the GP (49 %). The proportion of men
that had received prior urological care was higher among
dutasteride users than among finasteride users. The dur-
ation of the first 5-ARI treatment episode was on average
Table 1 General characteristics of men with BPH using finasteride or dutasteride
Dutasteride Finasteride
monotherapy & alpha-blocker monotherapy & alpha-blocker
N = 3,147 N = 8,675 N = 2,264 N = 3,517
n (%) n (%) n (%) n (%)
Age at cohort entry
50–54 years 150 (5) 330 (4) 172 (8) 148 (4)
55–59 years 320 (10) 860 (10) 255 (11) 371 (11)
60–64 years 468 (15) 1,541 (18) 341 (15) 577 (16)
65–79 years 1,659 (53) 4,681 (54) 1,101 (49) 1,847 (53)
80–84 years 330 (10) 848 (10) 246 (11) 378 (11)
85–89 years 169 (5) 348 (4) 101 (4) 151 (4)
≥ 90 51 (2) 67 (1) 48 (2) 45 (1)
Mean (±SD) 70 ± 10 70 ± 9 69 ± 10 70 ± 9
Prescriber of first 5-ARI
Urologist 1,705 (54) 5,053 (58) 653 (29) 1,412 (40)
GP 1,063 (34) 2,242 (26) 1,275 (56) 1,546 (44)
Other 379 (12) 1,380 (16) 336 (15) 559 (16)
Prior use of urological care
Yes 2,055 (65) 6,164 (71) 943 (42) 1,946 (55)
History of bladder or kidney stones
Yes 50 (2) 148 (2) 16 (1) 48 (1)
Comorbidities
Hypertension 1,653 (53) 4,444 (51) 1,116 (49) 1,771 (50)
Hypercholesterolemia 1,060 (34) 2,948 (34) 662 (29) 1,094 (31)
Diabetes type I 42 (1) 113 (1) 50 (2) 73 (2)
Diabetes type II 322 (10) 930 (11) 209 (9) 372 (11)
Parkinson’s disease 42 (1) 148 (2) 41 (2) 50 (1)
Multiple sclerosis 1 (<0.5) 1 (<0.5) 0 (0) 2 (<0.5)
Chronic disease score
0–3 1,402 (45) 3,987 (46) 1,137 (50) 1,634 (46)
4–7 939 (30) 2,516 (29) 619 (27) 1,017 (29)
≥ 8 806 (26) 2,172 (25) 508 (22) 866 (25)
Mean (±SD) 5 ± 4 5 ± 4 4 ± 4 5 ± 4
Adherence (MPR 5-ARI) (%)
Mean (±SD) 84 ± 13 85 ± 13 81 ± 14 84 ± 13
Database follow-up after cohort entry date
≥ 1 year 2,264 (100) 3,517 (100) 3,147 (100) 8,675 (100)
≥ 2 years 1,906 (84) 2,975 (85) 2,361 (75) 6,395 (74)
≥ 3 years 1,596 (70) 2,463 (70) 1,700 (54) 4,526 (52)
≥ 4 years 1,291 (57) 1,991 (57) 1,115 (35) 2,972 (34)
≥ 5 years 970 (43) 1,490 (42) 618 (20) 1,715 (20)
SD standard deviation, IQR interquartile range, MPR medication possession rate
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17 months for men receiving monotherapy of either finas-
teride or dutasteride. For men on combination therapy,
the duration of the first 5-ARI treatment episode was on
average 20 months for men on finasteride combination
therapy and 18 months for men on dutasteride combin-
ation therapy.
Incidence of outcomes
The incidence of BPH-related prostate surgery among
men using finasteride ranged from 12 per 1,000 person-
years among those using monotherapy prescribed by a
GP to 472 per 1,000 person-years among those using
combination therapy prescribed by a urologist (Table 2).
For men using dutasteride this was 10 per 1,000 person-
years among those using monotherapy prescribed by a
GP to 248 per 1,000 person-years among those using
combination therapy prescribed by a urologist. A trans-
urethral resection of the prostate (TURP) was most
common in all cohorts (data not shown).
Figure 1 shows the proportion of men free of BPH-
related prostate surgery over time, stratified by type of
initial BPH treatment and prescriber. Overall, dutaste-
ride users had a lower risk of BPH-related prostate sur-
gery than finasteride users. The crude HR was 0.83 (95 %
CI: 0.62–1.10), however when adjusted for geographic
location, cohort (mono- or combination therapy), adher-
ence with 5-ARI treatment, prescriber, chronic disease
score and number of GP visits the HR was 0.75 (95 % CI:
0.56–0.99). The strongest confounder was the initial pre-
scriber. This lower risk was seen for men on monotherapy
(adjusted HR: 0.73; 95 % CI: 0.54–0.98) as well as
combination therapy (adjusted HR: 0.85; 95 % CI: 0.74–
0.97) (Table 2). This association, however, was only
present among men with a first dispensing from a urolo-
gist (HR: 0.77; 95 % CI: 0.46–1.30 for men on monother-
apy and HR: 0.62; 95 % CI: 0.50–0.78 for combination
therapy), while there was no difference in the risk of BPH-
related prostate surgery among men with a first dispensing
from a GP. In a sensitivity analysis, BPH-related prostate
surgery was determined during total BPH treatment (cen-
soring upon changes in alpha-blocker use) and in another
sensitivity analysis during 5-ARI treatment (regardless of
alpha-blocker use) with a wash-out period of 6 months
after discontinuation. The difference in incidence of BPH-
related prostate surgery between mono- and combination
therapy remained, but the association with type of 5-ARI
was less clear.
Only 1 % of the finasteride or dutasteride users were
admitted for AUR during the first 5-ARI treatment
episode. The incidence rates were 6 per 1,000 person-
years for men on dutasteride monotherapy, 5 per 1,000
person-years for men on finasteride monotherapy, 9 per
1,000 person-years for men on dutasteride combination
therapy and 5 per 1,000 person-years for men on finaste-
ride combination therapy. Due to the low number of
men admitted for AUR, no HR could be calculated.
Discussion
To our knowledge, this is the first population-based
study to report the incidence of BPH-related prostate
surgery and AUR among men using dutasteride or finas-
teride in the Netherlands. Disease severity was
Table 2 Hazard ratios of BPH-related prostate surgery among men with BPH using finasteride or dutasteride












PY (95 % CI)
Hazard ratio




Overall 0.83 (0.62–1.10) 0.75 (0.56–0.99)b
Monotherapy 86 (4) 3,132 28 (22–34) 108 (3) 4,356 25 (20–30) 0.85 (0.64–1.13) 0.73 (0.54–0.98)c
Combination
therapy
317 (9) 5,646 56 (50–63) 767 (9) 12,685 61 (56–65) 0.91 (0.80–1.04) 0.85 (0.74–0.97)c
Prescriber: GP
Monotherapy 14 (1) 1,201 12 (6–20) 9 (1) 915 10 (5–19) 0.91 (0.39–2.13) -g
Combination
therapy
44 (4) 1,710 26 (19–35) 74 (4) 2389 31 (24–39) 1.07 (0.74–1.56) 1.10 (0.76–1.60)d
Prescriber: Urologist
Monotherapy 26 (11) 142 183 (120–268) 45 (7) 433 104 (76–139) 0.56 (0.35–0.92) 0.77 (0.46–1.30)d
Combination
therapy
105 (24) 223 472 (386–571) 272 (16) 1097 248 (219–279) 0.53 (0.42–0.66) 0.62 (0.50–0.78)e
PY person-years, CI confidence interval, GP general practitioner; aAdjusted for geographic location; bAdjusted for geographic location, cohort (mono- or combination
therapy), adherence with 5-ARI treatment, prescriber, chronic disease score and number of GP visits); cAdjusted for geographic location, adherence with 5-ARI treatment,
prescriber and number of GP visits; dAdjusted for geographic location and adherence with 5-ARI treatment; eAdjusted for geographic location, adherence with 5-ARI
treatment and number of drug dispensings; fpercentage of patients with an event in the specific group; gNone of the covariates were associated with BPH-related
prostate surgery or 5-ARI treatment
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accounted for by stratifying the results by type of ther-
apy (mono- or combination with alpha-blocker) and pre-
scriber (GP or urologist) in the absence of information
on symptom severity, flow rate parameter, serum PSA or
prostate size. In line with previous retrospective studies
it was confirmed that the risk of BPH-related prostate
surgery was lower among men using dutasteride com-
pared to men using finasteride. The association was
observed with either mono- or alpha-blocker combin-
ation therapy, however only among men who received
their prescription from a urologist. Both dutasteride and
finasteride blocks the type 2 5-alpha reductase enzymes
and converts testosterone into DHT, which makes them
both effective treatments for BPH [6, 7]. Dutasteride also
blocks the type 1 5-alpha reductase enzymes which may
suggest the possibility of improved outcomes with this
treatment. Furthermore, dutasteride has a longer half-
life compared to finasteride (approximately 4 weeks vs
6 h), which also might lead to better efficacy with
dutasteride [6, 20].
The incidence of BPH-related prostate surgery was
higher among men on combination therapy, which may
reflect the treatment choices based on perceived severity
of the condition. Furthermore, the incidence of BPH-
related prostate surgery was higher in men treated by
urologists compared to those treated by GPs. This
difference may be explained by the fact that the choice
for surgery takes place in secondary care. According to
Dutch guidelines, watchful waiting is advised for patients
without complications and with mild symptoms and/
complaints [21]. This is mainly based on the finding that
the effectiveness of both drug and invasive treatment in
these patients is limited, especially if it is weighed
against the potential side effects or complications.
Patients with severe symptoms who do not benefit
enough from lifestyle changes should be treated with an
alpha-blocker according to Dutch guidelines. When re-
sults of alpha-blocker treatment are unsatisfactory after
6 weeks, the medication should be stopped and the
patients should be referred to a specialist to discuss the
possibilities of invasive procedures. Treatment with a 5-
alpha reductase inhibitor (finasteride or dutasteride) is
an appropriate option for patients with moderate to
severe complaints and a prostate volume >30–40 ml. If a
fast reduction of complaints is desired, a 5-alpha reduc-
tase inhibitor can be given (temporarily) in combination
with an alpha-blocker. When other possible causes of
BPH are suspected, for example prostate cancer, the
primary care guidelines refer the patient to a specialist
for additional examination [21]. Furthermore, when the
symptoms are severe and surgical treatment is the only
option, the patient will be directly referred to a specialist.
Fig. 1 Kaplan-Meier survival curve showing the proportion of men free of BPH-related prostate surgery, stratified by type of initial BPH treatment and
prescriber. a) dutasteride or finasteride monotherapy prescribed by GP, b) dutasteride or finasteride monotherapy prescribed by urologist, c) dutasteride
or finasteride & alpha-blocker prescribed by GP, d) dutasteride or finasteride & alpha-blocker prescribed by urologist
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Urologists have the choice to recommend surgical treat-
ment and conduct the surgery themselves. This is not the
case for GPs, who have to refer patients when a BPH-
related prostate surgery is needed. As a result, BPH
patients in primary care are less severe and patients have
less room for improvement. This was also shown in a
study performed among four GP practices in the
Netherlands. In this study, it was shown that 30 % of the
BPH patients were immediately referred to the urologist.
For the majority of the patients, the main reason for refer-
ral was the nature and the severity of the micturition, a
suspicious rectal toucher or requested by the patient [22].
Until the early 90s, the choice of therapy in patients
with BPH consisted of either watchful waiting or
surgical treatment. In the last 15 years, many new
therapies were introduced of which alpha-blockers
and 5-ARI are most common.
Extending the follow-up with 6 months after discon-
tinuation of 5-ARI affected the incidence rates only
marginally. Applying a more strict definition of treatment,
i.e. not only continuous 5-ARI treatment but also no
change in alpha-blocker therapy, resulted in a more pro-
nounced difference in rates between mono- and combin-
ation therapy, but the difference between dutasteride and
finasteride users did not change.
Finasteride became available on the European market
in 1992, while dutasteride became available in 2002. As
new drugs are usually first given to a selected group of
patients, mostly the more severe, this may create a bias
in favor of older products and thus a confounded com-
parison of the risks of BPH-related prostate surgery
between dutasteride and finasteride. In order to assess
this potential introduction bias, a sensitivity analysis was
performed excluding men starting with 5-ARI between
2003 and 2006. However, excluding those years did not
change the comparison of risk of BPH-related prostate
surgery between dutasteride and finasteride. Therefore,
introduction bias seems unlikely. Furthermore, for this
study, data up to and including 2011 was used. As in
more recent years no substantial changes occurred with
respect to the management and treatment of BPH, major
changes in the association between type of 5-ARI and
BPH-related prostate surgery are not likely.
Consistent with the current results, a previous study
showed that dutasteride was associated with a lower risk
of BPH-related surgery (HR 0.75; 95 % CI: 0.58–0.98)
[13]. However, whether the patients in this study were
on monotherapy or combination therapy was not speci-
fied. In another study among men aged ≥50 years, no
significant difference in surgery rates was found between
patients using dutasteride or finasteride [12].
AUR was a relatively infrequent event in this study,
occurring in only 1 % of the men using finasteride or
dutasteride. AUR was probably underreported in this
study because the database did not capture emergency
department visits. In a previous study among patients
aged 50 years or older diagnosed with BPH, the rate of
AUR after 5 to 12 months was significantly lower in the
dutasteride group compared with the finasteride group
(5.3 % vs 8.3 %) [12].
Conclusions
In conclusion, the risk of BPH-related prostate surgery
was lower among men using dutasteride than among men
using finasteride. This association was present among
men treated with 5-ARI monotherapy as well as men
treated with 5-ARI combination therapy. The difference in
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